Pharma News

The FDA has issued a warning letter to a Lake Forest, Calif.-based biologics company, Invitrx Therapeutics, for selling unapproved allogenic cellular-derived drugs, including a human umbilical cord...

Bayer’s Nubeqa (darolutamide) plus androgen deprivation therapy (ADT) in combination with docetaxel has received marketing authorization from the UK’s Medicines and Healthcare products Regulato...

Full-Life Technologies, a radiotherapeutics company, has entered into an agreement to acquire Focus-X Therapeutics and its cancer-targeting radiopharmaceuticals. ...

Treatment with the investigational agent resulted in improvements in Alzheimer disease agitation, as well as significant delays in time to relapse and prevention of relapse. ...

C4X Discovery and AstraZeneca have inked a licensing deal for C4XD’s NRF2 Activator program to develop and market an oral therapy for inflammatory and respiratory diseases, focusing on chronic ob...

The FDA has pushed back its decision date for Gamida Cell’s Biologics License Application (BLA) for omidubicel — a drug that treats patients with blood cancer in need of a bone marrow transplan...

Aquatic Therapy Improves MS Fatigue, MS Disease Pathology Not Defined by Courses, Rituximab Shows Positive Effect in Myasthenia Gravis. Welcome to this special edition of Neurology News Network.&nb...

A common chemotherapy drug could carry a toxic inheritance for children and grandchildren of adolescent cancer survivors, Washington State University-led research indicates. ...

The European Commission has provided around €7 million ($7.2 million) in funding to a new project that aims to boost the ability of hospitals within the EU to collect real-world data (RWD) to gau...

The FDA has granted Fast Track designation to Palisade Bio’s investigational drug LB1148 to accelerate the return of bowel function following gastrointestinal surgery. ...

A new bill, the Breakthrough Therapies Act, would encourage the reclassification of MDMA and psilocybin from schedule I to schedule II drugs.

The European Commission (EC) has granted approval for AbbVie’s Skyrizi (risankizumab, 600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) to treat moderately to severely ac...